현대약품

004310KOSPI

40.5 / 100

Reference Date: 2026-10-23

Financial Score14.0 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 32.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hyundai Pharm focuses on the production and sale of prescription and OTC pharmaceuticals, food, cosmetics, and medical devices, supplying products such as hypertension medication Tenolmin, hair loss treatment Minoxil, and dietary fiber beverage Mieyro Haiiba both domestically and internationally. The company has established a competitive edge in the functional cosmetics market through its brand Labcle, which emphasizes eco-friendly ingredients and sustainable packaging, aligning with global green consumption trends.

Number of Employees

399people

Average Salary

71.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

71.88Industry Average 15.000.0Point

4.8x industry avg (risky)

PBR

2.69Industry Average 1.200.0Point

2.2x industry avg (risky)

ROE

3.12Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

11.82Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲1051.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (31%)

Current 6,900Won52-week high 14,34052-week low 3,545

1-month return0.0Point

1m -32.02% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.08)2026-10-15